School of Medicine
Showing 4,061-4,080 of 5,033 Results
-
Javaid I. Sheikh
Professor of Psychiatry and Behavioral Sciences, Emeritus
Current Research and Scholarly InterestsMy research focuses on studying phenomenology, vulnerability factors, and psychiatric and medical comorbidity of panic disorder in old age, as well as treatment responses to medication in elders with panic disorder. I am presently involved in establishing and extending our preliminary finding that Late-Onset Panic Disorder (LOPD) (onset at or after age 55) is a phenomenologically distinct syndrome from Early-Onset Panic Disorder (EOPD).
-
Andrew A. Shelton, MD, FACS, FACRS
Clinical Professor, Surgery - General Surgery
Current Research and Scholarly InterestsMultimodality treatment of rectal cancer
Sphincter preserving procedures for rectal cancer
Laparoscopic colon and rectal surgery
Surgical education -
Dennis Shem
Clinical Assistant Professor, Surgery - Plastic & Reconstructive Surgery
BioDr. Shem is a Clinical Assistant Professor in the Section of Dental Medicine and Surgery at Stanford University. He trained in Dental Oncology at Memorial Sloan Kettering Cancer Center, focusing on oral complications of cancer therapy and non-surgical management of patients with osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ). He also trained in Oral and Maxillofacial Pathology at Columbia University and has expertise in diagnosing and managing oral mucosal diseases.
As a dental oncologist and oral pathologist, he evaluates patients before and after organ and stem-cell transplant, radiation therapy, chemotherapy, and bisphosphonate therapy. He has particular interest in oral manifestations of systemic disease, oral complications of systemic therapy, and oral dysplasia. -
Prof Christopher Shen MD
Adjunct Professor, Medicine - Surgery
Academic Staff - Hourly - CSL, SurgeryBioDr. Christopher Shen is an Adjunct Professor in the Stanford School of Medicine, the Director of Global Programs at the Stanford Mussallem Center for Biodesign, and a member of the Stanford Biodesign Leadership Council. Dr. Shen is also the Founding Executive Director of the Singapore Stanford Biodesign Program.
Dr. Shen has been a longstanding member of the Stanford community since 1991, completing degrees in Biological Sciences, Biomechanical Engineering, Business, and Medicine. He has been teaching graduate and undergraduate students since 2001.
A strong proponent of interdisciplinary and experiential education, Dr. Shen has dedicated his career to teaching medical, engineering, and business students at Stanford and abroad in foundational concepts underpinning design-thinking, clinical immersion, ideation, rapid prototyping, innovation, and entrepreneurship. In addition, Dr. Shen is responsible for establishing and/or managing collaborations between Stanford and Biodesign-like programs on every continent except Antarctica! He continues to annually mentor diverse groups of students to develop and implement innovative medical solutions to serve patients around the world.
Dr. Shen is the founding and current U.S. Executive Director of Singapore Stanford Biodesign since its inception in 2010. As the first Biodesign program in East Asia, its mission is to train the next generation of medical technology innovators throughout the Pacific Rim, focusing on the unique medical needs in the region. Supported by Singapore's national level research institute, the Agency for Science, Technology, and Research (ASTAR), and the National Research Foundation (NRF), the program has uniquely built bridges across Asia, spanning Singapore, China, Indonesia, Taiwan, Korea, Australia, and Malaysia. In total, the program has trained 60 Fellows and hundreds of students throughout the region.
Dr. Shen is also a Partner at Novo Holdings, the asset manager of the Novo Foundation, one of the largest philanthropic organizations in the world. With headquarters in Denmark, Novo Holdings is committed to investing in innovative companies that improve the health of people and planet. Dr. Shen started his career in medical innovation as a Senior Design Engineer at Guidant Neurovascular, where he was the principal inventor of one of the original stentriever devices for ischemic stroke. He has been issued twelve patents in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen was a Stanford Asia/Pacific Scholar and a Paul & Daisy Soros Fellow. -
Jeanne Shen
Associate Professor of Pathology
Current Research and Scholarly InterestsGastrointestinal and pancreatobiliary pathology, with major emphasis on GI and pancreatic neoplasia, inflammatory bowel disease, biodesign innovation, and the application of machine learning to digital pathology.
-
Kang Shen
Vincent V.C. Woo Director, Wu Tsai Neurosciences Institute, Frank Lee and Carol Hall Professor and Professor of Biology and of Pathology
Current Research and Scholarly InterestsThe connectivity of a neuron (its unique constellation of synaptic inputs and outputs) is essential for its function. Neuronal connections are made with exquisite accuracy between specific types of neurons. How each neuron finds its synaptic partners has been a central question in developmental neurobiology. We utilize the relatively simple nervous system of nematode C. elegans, to search for molecules that can specify synaptic connections and understand the molecular mechanisms of synaptic as
-
Luyao Shen, MD
Clinical Associate Professor, Radiology
Current Research and Scholarly InterestsGU and Gyn clinical imaging
-
Sam Shen
Clinical Professor, Emergency Medicine
Current Research and Scholarly InterestsEmergency Department process improvement
Digital Health
ED operations
ED innovations -
Yelizaveta Sher, MD, FACLP
Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Clinical Professor (By courtesy), Medicine - Pulmonary, Allergy & Critical Care MedicineBioDr. Sher received her BA from UC Berkeley and MD from Washington University in St. Louis. She completed Residency in Psychiatry and Fellowship in Psychosomatic Medicine at Stanford University Medical Center. She has been a part of Psychosomatic Medicine Faculty, now a Division of Medical Psychiatry, at Stanford since 2013. Her areas of clinical and research interests include psychiatric comorbidities in patients with pulmonary disorders. In particular, she specializes in mental health of patients with cystic fibrosis as well as lung and heart transplant patients. She consults on patients hospitalized on medical and surgical units as well as sees patients in outpatient clinics. She serves as the Director of Psychiatric and Psychological Services for the Adult Cystic Fibrosis Clinic and Chief of Psychosomatic Medicine Clinic. She has published many articles and book chapters and edited several books related to her fields of interest and expertise.
-
Gavin Sherlock
Professor of Genetics
On Leave from 03/02/2026 To 03/31/2026Current Research and Scholarly InterestsEvolution and the adaptive landscape using yeast as a model; Defining yeast transcriptomes; chromosomal evolution in hybrid yeast species
-
Seth Lawrence Sherman, MD
Associate Professor of Orthopaedic Surgery
Current Research and Scholarly InterestsMy research focuses on ways to augment tissue healing, improve human performance, and prevent musculoskeletal injuries. Approaching these challenges through parallel basic science and clinical pathways, our team works from the “bedside to the bench and back to the bedside”, identifying areas of clinical need to deliver evidence-based solutions for patients.
We collaborates with orthopaedic surgeons, non-surgical physicians, and researchers within bioengineering, human performance, and musculoskeletal imaging across the Stanford campus. The team is developing novel methods to accurately record human movement (including wearable technology, phone-based systems), rapid MRI imaging protocols, and exploring the use of biomarkers to track injury and recovery. This research builds on my earlier work, which utilized portable, inexpensive software for Microsoft Kinect to detect knee injury risk in youth athletes performing a drop vertical jump test. The team’s multifaceted goal is: 1) develop innovative methods to screen for injury risk (i.e. youth athlete non-contact ACL), 2) create targeted intervention programs to reduce risk, 3) enhance athletic performance; and 4) improve accuracy of return to play testing following injury/surgery (i.e. clinical evaluation, biomarkers, functional tests, imaging analysis for healing).
In the laboratory,our team investigates cellular and molecular deficiencies in tissue types including tendon, ligament, articular cartilage, and meniscus. By understanding aberrant pathways leading to tissue injury, they can identify innovative therapeutic targets for intervention. In collaboration with the Genetic Engineering and Synthetic Biology laboratories, Dr. Sherman’s research has explored the role of orthobiologic agents such as platelet rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) for tissue healing in patella tendinopathy (the breakdown of collagen in a tendon). Our lab is also investigating the use of CBD for musculoskeletal applications as an alternative to commonly used local anesthetics and cortisone derivatives. In my earlier work, we researched the cellular toxicity of such applications.
In addition to basic science research, I have helped to build a Sports Medicine clinical research team that includes several full-time clinical research coordinators, residents, fellows, and students. The team collects prospective outcomes on their patients using a novel data collection platform called Patient IQ. The group is part of the JUPITER study which is the largest, multicenter study ever assembled in patellofemoral instability. They are additionally planning to enroll in FDA-approved clinical studies investigating pioneering strategies for knee cartilage restoration, joint preservation, and orthobiologic injections for osteoarthritis. Recent clinical publications explore outcomes in meniscus preservation and transplantation, medial patellofemoral ligament reconstruction, osteochondral allograft and matrix-induced autologous chondrocyte implantation (MACI), and surgical augmentation using PRP/BMAC. The clinical research team actively reports results of non-surgical and surgical interventions to continue to introduce new knowledge to the field, with the goal of improved patient outcome.
